Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
Author:
Affiliation:
1. Department of Medicine I, Division of Oncology, Medical University of Vienna , Vienna, Austria
2. Comprehensive Cancer Center Vienna , Wien, Austria
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1792443
Reference66 articles.
1. Cancer statistics, 2018
2. Molecular portraits of human breast tumours
3. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
4. ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region;Frontiers in Pharmacology;2024-08-06
2. Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases;Neuro-Oncology;2024-07-04
3. Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease;memo - Magazine of European Medical Oncology;2024-06-04
4. Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases;Protein Science;2024-03-19
5. Role of the Tumor Microenvironment in Mediating Resistance to Anti-HER2 Antibodies;Critical Reviews™ in Oncogenesis;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3